Published in Microsc Res Tech on August 15, 2003
Apatite-mediated actin dynamics in resorbing osteoclasts. Mol Biol Cell (2004) 1.91
The anion exchanger Ae2 is required for enamel maturation in mouse teeth. Matrix Biol (2007) 1.43
Nano-topography sensing by osteoclasts. J Cell Sci (2010) 1.19
The regulation of osteoclast function and bone resorption by small GTPases. Small GTPases (2011) 1.11
Rab3D regulates a novel vesicular trafficking pathway that is required for osteoclastic bone resorption. Mol Cell Biol (2005) 1.08
Secretion of L-glutamate from osteoclasts through transcytosis. EMBO J (2006) 1.07
Therapeutic inhibition of cathepsin K-reducing bone resorption while maintaining bone formation. Bonekey Rep (2012) 0.98
Disruption of the Man-6-P targeting pathway in mice impairs osteoclast secretory lysosome biogenesis. Traffic (2011) 0.94
Surface-induced regulation of podosome organization and dynamics in cultured osteoclasts. Chembiochem (2009) 0.93
V-ATPase subunit ATP6AP1 (Ac45) regulates osteoclast differentiation, extracellular acidification, lysosomal trafficking, and protease exocytosis in osteoclast-mediated bone resorption. J Bone Miner Res (2012) 0.93
Biology of Bone Tissue: Structure, Function, and Factors That Influence Bone Cells. Biomed Res Int (2015) 0.92
Podosome organization drives osteoclast-mediated bone resorption. Cell Adh Migr (2014) 0.92
Polarization and secretion of cathepsin K precede tartrate-resistant acid phosphatase secretion to the ruffled border area during the activation of matrix-resorbing clasts. J Bone Miner Metab (2005) 0.90
Regulation of osteoclast polarization. Odontology (2007) 0.89
Bioceramics composition modulate resorption of human osteoclasts. J Mater Sci Mater Med (2005) 0.88
Clathrin-dependent endocytosis of membrane-bound RANKL in differentiated osteoclasts. Eur J Histochem (2010) 0.86
Tctex-1, a novel interaction partner of Rab3D, is required for osteoclastic bone resorption. Mol Cell Biol (2011) 0.85
Breast cancer at bone metastatic sites: recent discoveries and treatment targets. J Cell Commun Signal (2011) 0.81
Modulation of osteoclast differentiation and bone resorption by Rho GTPases. Small GTPases (2014) 0.80
Impaired prenylation of Rab GTPases in the gunmetal mouse causes defects in bone cell function. Small GTPases (2011) 0.78
Novel perspectives on the transcytotic route in osteoclasts. Bonekey Rep (2013) 0.78
Study of Osteoclast Adhesion to Cortical Bone Surfaces: A Correlative Microscopy Approach for Concomitant Imaging of Cellular Dynamics and Surface Modifications. ACS Appl Mater Interfaces (2015) 0.78
In vitro model of bone to facilitate measurement of adhesion forces and super-resolution imaging of osteoclasts. Sci Rep (2016) 0.76
Dynamics of the sealing zone in cultured osteoclasts. Cytoskeleton (Hoboken) (2017) 0.75
β3 integrin expression is required for invadopodia-mediated ECM degradation in lung carcinoma cells. PLoS One (2017) 0.75
Serum osteocalcin is not associated with glucose but is inversely associated with leptin across generations of nondiabetic women. J Clin Endocrinol Metab (2012) 1.49
Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res (2002) 1.46
Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol (2002) 1.38
Isolated primary osteocytes express functional gap junctions in vitro. Cell Tissue Res (2005) 1.36
Conditioned medium from osteocytes stimulates the proliferation of bone marrow mesenchymal stem cells and their differentiation into osteoblasts. Exp Cell Res (2004) 1.28
Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption. Clin Lab (2006) 1.22
Osteocytes inhibit osteoclastic bone resorption through transforming growth factor-beta: enhancement by estrogen. J Cell Biochem (2002) 1.22
Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonberg disease (type II autosomal dominant osteopetrosis). Clin Chem (2004) 1.17
Biochemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Miner Res (2003) 1.16
Intracellular machinery for matrix degradation in bone-resorbing osteoclasts. J Bone Miner Res (2004) 1.15
Osteoclast ruffled border has distinct subdomains for secretion and degraded matrix uptake. Traffic (2003) 1.14
The critical role of IL-34 in osteoclastogenesis. PLoS One (2011) 1.14
FGF-8 is involved in bone metastasis of prostate cancer. Int J Cancer (2008) 1.13
Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption. J Bone Miner Res (2005) 1.12
Associations between homocysteine, bone turnover, BMD, mortality, and fracture risk in elderly women. J Bone Miner Res (2007) 1.11
Release of intact and fragmented osteocalcin molecules from bone matrix during bone resorption in vitro. J Biol Chem (2004) 1.11
Death of osteocytes turns off the inhibition of osteoclasts and triggers local bone resorption. Biochem Biophys Res Commun (2005) 1.11
Monocyte-macrophage system as a target for estrogen and selective estrogen receptor modulators. Ann N Y Acad Sci (2006) 1.06
Possible role of direct Rac1-Rab7 interaction in ruffled border formation of osteoclasts. J Biol Chem (2005) 1.01
Bone turnover markers and prediction of fracture: a prospective follow-up study of 1040 elderly women for a mean of 9 years. J Bone Miner Res (2010) 0.99
Inactivation of estrogen receptor α in bone-forming cells induces bone loss in female mice. FASEB J (2012) 0.98
Breast cancer cells with inhibition of p38alpha have decreased MMP-9 activity and exhibit decreased bone metastasis in mice. Clin Exp Metastasis (2004) 0.98
Membrane-bound carbonic anhydrases in osteoclasts. Bone (2006) 0.98
Bone marrow cell differentiation induced by mechanically damaged osteocytes in 3D gel-embedded culture. J Bone Miner Res (2006) 0.97
Human mesenchymal stem cell derived osteoblasts degrade organic bone matrix in vitro by matrix metalloproteinases. Matrix Biol (2005) 0.96
Serial assessment of serum bone metabolism markers identifies women with the highest rate of bone loss and osteoporosis risk. J Clin Endocrinol Metab (2008) 0.95
Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J Bone Miner Res (2005) 0.93
Biochemical markers of bone turnover are influenced by recently sustained fracture. Bone (2005) 0.93
Intracellular membrane trafficking pathways in bone-resorbing osteoclasts revealed by cloning and subcellular localization studies of small GTP-binding rab proteins. Biochem Biophys Res Commun (2002) 0.92
Regulation of osteoblast differentiation: a novel function for fibroblast growth factor 8. Endocrinology (2006) 0.92
Estrogen responsiveness of bone formation in vitro and altered bone phenotype in aged estrogen receptor-alpha-deficient male and female mice. Eur J Endocrinol (2005) 0.91
Transient 100 nM dexamethasone treatment reduces inter- and intraindividual variations in osteoblastic differentiation of bone marrow-derived human mesenchymal stem cells. Tissue Eng Part C Methods (2012) 0.91
Receptor tyrosine kinase inhibition causes simultaneous bone loss and excess bone formation within growing bone in rats. Toxicol Appl Pharmacol (2011) 0.91
Evidence for the role of osteocytes in the initiation of targeted remodeling. Technol Health Care (2009) 0.91
RNA interference tolerates 2'-fluoro modifications at the Argonaute2 cleavage site. Chem Biodivers (2007) 0.89
Overexpression of vascular endothelial growth factor C increases growth and alters the metastatic pattern of orthotopic PC-3 prostate tumors. BMC Cancer (2009) 0.89
Estrogen and the selective estrogen receptor modulator (SERM) protection against cell death in estrogen receptor alpha and beta expressing U2OS cells. Mol Cell Endocrinol (2008) 0.88
The effects of tamoxifen and toremifene on bone cells involve changes in plasma membrane ion conductance. J Bone Miner Res (2003) 0.88
Inhibition of the osteoclast V-ATPase by small interfering RNAs. FEBS Lett (2005) 0.88
Phosphatase and oxygen radical-generating activities of mammalian purple acid phosphatase are functionally independent. Biochem Biophys Res Commun (2002) 0.88
Urinary osteocalcin as a marker of bone metabolism. Clin Chem (2005) 0.88
Potential function for the ROS-generating activity of TRACP. J Bone Miner Res (2003) 0.87
Macrophages overexpressing tartrate-resistant acid phosphatase show altered profile of free radical production and enhanced capacity of bacterial killing. Biochem Biophys Res Commun (2005) 0.86
Cystatin B as an intracellular modulator of bone resorption. Matrix Biol (2006) 0.86
Degradation of hydroxyapatite in vivo and in vitro requires osteoclastic sodium-bicarbonate co-transporter NBCn1. Matrix Biol (2010) 0.86
A rationale for osteoclast selectivity of inhibiting the lysosomal V-ATPase a3 isoform. Calcif Tissue Int (2010) 0.86
Pharmacological sequestration of intracellular cholesterol in late endosomes disrupts ruffled border formation in osteoclasts. J Bone Miner Res (2005) 0.86
Overexpression of cathepsin K accelerates the resorption cycle and osteoblast differentiation in vitro. Bone (2008) 0.86
FGF-8b induces growth and rich vascularization in an orthotopic PC-3 model of prostate cancer. J Cell Biochem (2009) 0.86
The architecture of microtubular network and Golgi orientation in osteoclasts--major differences between avian and mammalian species. Exp Cell Res (2003) 0.84
Bisphosphonate induced growth inhibition of breast cancer cells is augmented by p38 inhibition. Breast Cancer Res Treat (2003) 0.83
Improved methods for testing antiresorptive compounds in human osteoclast cultures. J Bone Miner Metab (2008) 0.82
Sequence and TLR9 independent increase of TRACP expression by antisense DNA and siRNA molecules. Biochem Biophys Res Commun (2007) 0.81
Tumor necrosis factor-alpha induces interleukin-6 production via extracellular-regulated kinase 1 activation in breast cancer cells. Breast Cancer Res Treat (2003) 0.81
Rab13 is upregulated during osteoclast differentiation and associates with small vesicles revealing polarized distribution in resorbing cells. J Histochem Cytochem (2012) 0.81
Recombinant VSV G proteins reveal a novel raft-dependent endocytic pathway in resorbing osteoclasts. Exp Cell Res (2008) 0.80
Effects of proteolysis and reduction on phosphatase and ROS-generating activity of human tartrate-resistant acid phosphatase. Arch Biochem Biophys (2006) 0.79
Expression of metastasin S100A4 is essential for bone resorption and regulates osteoclast function. Biochim Biophys Acta (2013) 0.79
Novel perspectives on the transcytotic route in osteoclasts. Bonekey Rep (2013) 0.78
Analysis by siRNA_profile program displays novel thermodynamic characteristics of highly functional siRNA molecules. Source Code Biol Med (2008) 0.78
Tartrate-resistant acid phosphatase 5B circulates in human serum in complex with alpha2-macroglobulin and calcium. Biochem Biophys Res Commun (2003) 0.78
Identification of novel proteolytic forms of osteocalcin in human urine. Biochem Biophys Res Commun (2003) 0.77
Overexpression of human hydroxysteroid (17beta) dehydrogenase 2 induces disturbance in skeletal development in young male mice. J Bone Miner Res (2008) 0.76
Urinary osteocalcin and serum pro-C-type natriuretic peptide predict linear catch-up growth in infants. J Bone Miner Res (2012) 0.76
Skeletal changes in transgenic male mice expressing human cytochrome p450 aromatase. J Bone Miner Res (2004) 0.76
Clinical performance of six different serum tartrate-resistant acid phosphatase assays for monitoring alendronate treatment. Clin Lab (2008) 0.75
Urinary osteocalcin is a useful marker for monitoring the effect of alendronate therapy. Clin Chem (2005) 0.75